Profile details
Profil Shannon O'Hara
Shannon is an Associate in our New York office primarily supporting our Life Sciences Transactions team. She advises companies in the healthcare, pharmaceutical and biotech space on a variety of transactions, including mergers and acquisitions, licensing agreements, commercial agreements and corporate reorganizations.
Prior to becoming a lawyer, Shannon conducted graduate-level quantitative research analyzing the relationship between ecotoxicological factors and human disease. She has also previously worked as a program coordinator for a university digital health center.
Mandate
- Merz Therapeutics on its $185 million acquisition of the assets of Acorda Therapeutics, Inc. through a court structured 363 sale process under the U.S. Bankruptcy Code.
- Johnson & Johnson on its $13.1 billion acquisition of Shockwave Medical, Inc.
- Novartis on its exclusive license agreement with Arvinas, Inc. for the global development and commercialization of a prostate cancer treatment.
- Roivant Sciences on its sale of Dermavant to Organon for up to $1.2 billion.
- Cencora (f/k/a AmerisourceBergen) on its pending $4.6 billion acquisition of Retina Consultants of America.
- AstraZeneca on its acquisition of Gracell Biotechnologies.
Qualifikationen
Education
- Duke University School of Law, J.D., 2023
- Notes Editor, Duke Law Journal
- Duke University Nicholas School of the Environment, M.E.M., Ecotoxicology, 2023
- University of California, Berkeley, B.S., Molecular Environmental Biology, 2019
Bar Admission
- New York, 2024
- Pennsylvania, 2023